Grifols ( (ES:GRF) ) has issued an update.
Grifols reported record results for fiscal year 2024, with significant revenue growth and improved cash flow, driven by strong performance in its Biopharma division and strategic initiatives. The company achieved all planned innovation milestones, reduced leverage, and strengthened its balance sheet, positioning itself for sustainable growth beyond 2025.
More about Grifols
Grifols is a global healthcare company that specializes in the production of plasma-derived medicines. It focuses on biopharmaceuticals and diagnostics, with a strong emphasis on innovation and strategic alliances to enhance its market position.
YTD Price Performance: 5.28%
Average Trading Volume: 184,698
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €5.91B
For an in-depth examination of GRF stock, go to TipRanks’ Stock Analysis page.